Zoetis Inc. (NYSE:ZTS) Receives $178.89 Average Target Price from Brokerages

Zoetis Inc. (NYSE:ZTS) has received a consensus rating of “Moderate Buy” from the twelve analysts that are covering the company, MarketBeat reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $178.8889.

ZTS has been the subject of a number of research reports. Stifel Nicolaus reduced their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. UBS Group lowered their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, JPMorgan Chase & Co. lowered their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th.

Zoetis Stock Performance

ZTS stock opened at $118.69 on Friday. The business has a 50 day moving average of $133.77 and a 200-day moving average of $147.57. The firm has a market cap of $52.31 billion, a PE ratio of 19.98, a P/E/G ratio of 2.46 and a beta of 0.97. Zoetis has a 12-month low of $115.25 and a 12-month high of $181.85. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 2nd. Investors of record on Friday, October 31st were paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Institutional Investors Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis during the 1st quarter worth about $25,000. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at approximately $29,000. Finally, REAP Financial Group LLC grew its stake in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.